Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SCB-1019T Revaccination in Older Adults Previously Vaccinated with Arexvy
NCT06843317Phase 1Recruiting
- Sponsor
- Clover Biopharmaceuticals
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of SCB-1019 in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Clover Biopharmaceuticals. Primary endpoint: Safety and reactogenicity of revaccination with SCB-1019T vaccine at 7 days. Started Mar 2025; status: recruiting.
02
Drugs
SCB-1019
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06843317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843317.